Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 11/20 | 0.60 |
| ▸ | CCND1 | P24385 | 10/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.60 |
| ▸ | CDK2 | P24941 | 7/20 | 0.60 |
| ▸ | CDK1 | P06493 | 6/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.60 |
| ▸ | CCND2 | P30279 | 5/20 | 0.60 |
| ▸ | CCND3 | P30281 | 5/20 | 0.60 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.60 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.60 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.50 |
| ▸ | CDK9 | P50750 | 2/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976928 | 0.96 | CDK4 (0.54) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL7715488 | 0.90 | RPS6KA6 (0.64) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL7714435 | 0.89 | RPS6KA6 (0.63) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL11976916 | 0.86 | CDK4 (0.60) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL5519312 | 0.83 | CDK4 (0.56) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL11976929 | 0.82 | LRRK2 (0.54) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL12639647 | 0.81 | CDK4 (0.57) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL17396416 | 0.80 | CDK4 (0.55) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL25046158 | 0.79 | RPS6KA6 (0.57) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL20418800 | 0.79 | RPS6KA6 (0.54) | CDK4CCND1CCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | NOVARTIS AG (CH) | 2018-07-26 | — | — | US | disclosed |
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | NOVARTIS AG (CH) | 2018-07-26 | — | — | US | disclosed |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | NOVARTIS AG (CH) | 2016-01-14 | — | — | US | disclosed |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | NOVARTIS AG (CH) | 2016-01-14 | — | — | US | disclosed |
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011130232-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | CDK4, CDK6, CDK8 | CDK4 1/4885CCND1 44/4885CCNE1 42/4885 |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CDK4 4/4885CCND1 615/4885CCNE1 623/4885 |
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | CDK4, CDK6, MTOR | CDK4 1/4885CCND1 76/4885CCNE1 57/4885 |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | CDK4, CDK6, CDKL4 | CDK4 1/4885CCND1 41/4885CCNE1 45/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | CDK4 4/4885CCND1 615/4885CCNE1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.